HANSA BIOPHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.93 USD | -9.98% |
|
-.--% | +29.82% |
| 05-31 | Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial | MT |
| 05-31 | Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial | CI |
Chart calendar Hansa Biopharma AB
62db98c27f5ed0b0c380eb635451.W39VZAS1V92Vr8GzPSbOLY4jeztuZW4qXpB230McUwI.KxIDKkCGFZCs7I6BYnyXG_RAPG4jOiwbFdpFpQAxPHA3ETgISoYNhNaChA~af49abfed50049a0c1760bd5b67ac699
Upcoming events on Hansa Biopharma AB
Past events on Hansa Biopharma AB
| 2024-06-10 | ABG Digitital Autoimmunity, Transplantation, and Inflammation Conference |
| 2024-06-05 09:40 | American Transplant Congress |
| 2024-06-04 10:15 | American Transplant Congress |
| 2024-06-04 09:15 | American Transplant Congress |
| 2024-06-03 13:40 | American Transplant Congress |
| 2024-06-02 09:15 | American Transplant Congress |
| 2024-05-26 | Roadshow |
| 2024-05-13 | Capital One Biotech Disruptors Conference |
| 2024-04-21 | Roadshow |
| 2024-04-18 08:00 | Q1 2024 Earnings Call |
| 2024-04-18 01:00 | Q1 2024 Earnings Release |
| 2024-04-15 | Van Lanschot Kempen Life Sciences Conference |
| 2024-04-07 | Needham Healthcare Conference |
| 2024-03-03 | TD Cowen Health Care Conference |
| 2024-02-27 | Ökonomisk Ugebrev Life Science Conference |
| 2024-02-13 | Redeye Regenerative Medicine/Cell Therapy Event |
| 2024-02-05 | Frankfurt MidCap Conference |
| 2024-02-02 08:00 | Q4 2023 Earnings Call |
| 2024-02-02 01:31 | Q4 2023 Earnings Release |
| 2024-01-07 | JPMorgan Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million SEK | Released Forecast Spread | 3,40 3,04 11.84% | 6,10 9,00 -32.24% | 33,9 32,4 4.53% | 155 146 5.55% | 134 134 0.31% | 252 |
|
EBITDA Million SEK | Released Forecast Spread | -352 -360 2.24% | -420 -394 -6.6% | -538 -501 -7.44% | -577 -565 -2.1% | -769 -754 -1.96% | -529 |
|
EBIT Million SEK | Released Forecast Spread | -360 -357 -0.84% | -423 -406 -4.24% | -547 -538 -1.65% | -587 -586 -0.11% | -788 -781 -1.02% | -589 |
|
Earnings before Tax (EBT) Million SEK | Released Forecast Spread | -360 -356 -1.15% | -421 -396 -6.17% | -548 -506 -8.37% | -608 -600 -1.32% | -831 -861 3.52% | -679 |
|
Net income Million SEK | Released Forecast Spread | -360 -356 -1.25% | -421 -396 -6.17% | -548 -506 -8.41% | -610 -601 -1.46% | -832 -864 3.71% | -679 |
|
EPS SEK | Released Forecast Spread | -9,00 -8,82 -2.04% | -9,98 -9,40 -6.13% | -12,3 -11,3 -9.41% | -13,6 -12,8 -5.91% | -15,8 -16,3 2.67% | -10,9 |
| Announcement Date | 06/02/20 | 04/02/21 | 03/02/22 | 02/02/23 | 02/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 S1 | 2021 S2 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million SEK | Released Forecast Spread | 13,5 24,0 -43.75% | 20,4 25,0 -18.4% | 30,3 5,28 473.81% | 26,4 15,0 75.72% | 67,1 23,7 183.18% | 30,8 31,0 -0.83% | 24,2 30,7 -21.12% | 36,7 35,6 3.01% | 22,8 22,8 0% | 50,4 50,0 0.82% | 56,0 54,0 3.7% | 50,7 | 70,4 | 61,8 | 67,8 | 71,8 |
|
EBITDA Million SEK | Released Forecast Spread | -135 0,00 - | -167 0,00 - | -139 0,00 - | -116 | -164 | -136 | -141 | -153 | -108 | -127 | ||||||
|
EBIT Million SEK | Released Forecast Spread | -236 -214 -10.28% | -311 | -135 -82,7 -63.21% | -168 0,00 - | -139 -171 18.56% | -145 -177 18.33% | -182 -137 -32.86% | -228 -169 -35.03% | -202 -193 -4.78% | -176 -169 -3.92% | -159 -170 6.35% | -161 | -142 | -150 | ||
|
Earnings before Tax (EBT) Million SEK | Released Forecast Spread | -237 -214 -10.53% | -312 -265 -17.58% | -138 -165 16.37% | -153 -173 11.19% | -147 -184 20.49% | -205 -160 -28.17% | -251 -188 -33.76% | -250 -217 -15.21% | -124 -196 36.59% | -219 -174 -25.82% | -176 | -170 | -171 | |||
|
Net income Million SEK | Released Forecast Spread | -237 -214 -10.52% | -312 -265 -17.66% | -138 -82,7 -67.33% | -170 0,00 - | -154 -173 10.9% | -147 -183 19.7% | -251 -188 -33.69% | -251 -217 -15.31% | -124 -196 36.49% | -219 -174 -25.77% | -176 | -170 | -171 | |||
|
EPS SEK | Released Forecast Spread | -5,32 -4,80 -10.83% | -7,01 -6,00 -16.83% | -3,11 -1,81 -72.3% | -3,82 -1,88 -103.73% | -3,45 -3,80 9.21% | -3,19 -4,14 22.95% | -3,92 -3,53 -11.05% | -4,79 -3,55 -35.12% | -4,78 -3,98 -20.25% | -2,36 -3,72 36.5% | -4,15 -3,19 -30.09% | -2,72 | -2,50 | -2,45 | -2,46 | -2,48 |
| Announcement Date | 15/07/21 | 03/02/22 | 21/04/22 | 19/07/22 | 20/10/22 | 02/02/23 | 20/04/23 | 20/07/23 | 26/10/23 | 02/02/24 | 18/04/24 | - | - | - | - | - |
| 2024-07-15 01:45 | ADDLIFE AB: Q2 2024 Earnings Release |
| 2024-07-21 | MEDPACE HOLDINGS, INC.: Q2 2024 Earnings Release (Projected) |
| 2024-07-23 | SYNGENE INTERNATIONAL LIMITED: Q1 2025 Earnings Release (Projected) |
| 2024-07-23 | ALKERMES PLC: Q2 2024 Earnings Release (Projected) |
| 2024-07-23 | IQVIA HOLDINGS INC.: Q2 2024 Earnings Release (Projected) |
| 2024-07-23 | ICON PUBLIC LIMITED COMPANY: Q2 2024 Earnings Release (Projected) |
| 2024-07-24 | LONZA GROUP AG: Q2 2024 Earnings Release |
| 2024-07-25 01:00 | BACHEM HOLDING AG: Q2 2024 Earnings Release |
| 2024-07-25 | PHARVARIS N.V.: Q2 2024 Earnings Release (Projected) |
| 2024-07-26 01:00 | BB BIOTECH AG: Q2 2024 Earnings Release |
Past sector events for Hansa Biopharma AB
| 2024-05-29 16:01 | IMMUNOVANT, INC.: Q4 2024 Earnings Release |
| 2024-05-23 07:00 | CUREVAC N.V.: Q1 2024 Earnings Release |
| 2024-05-22 01:00 | EVOTEC SE: Q1 2024 Earnings Release |
| 2024-05-21 17:14 | ALVOTECH: Q1 2024 Earnings Release |
| 2024-05-21 07:00 | EXSCIENTIA PLC: Q1 2024 Earnings Release |
| 2024-05-17 02:00 | BIOARCTIC AB: Q1 2024 Earnings Release |
| 2024-05-15 16:05 | CULLINAN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-15 07:00 | PERSPECTIVE THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-14 | GNI GROUP LTD.: Q1 2024 Earnings Release |
| 2024-05-14 16:05 | KYVERNA THERAPEUTICS, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- HNSA Stock
- HNSBF Stock
- Calendar Hansa Biopharma AB
